Effect of Magnesium on Dose of Rocuronium for Deep Neuromuscular Blockade

Seoul National University

Status: Completed

Conditions: Magnesium Sulfate Causing Adverse Effects in Therapeutic Use; Neuromuscular Blockade

Treatments: Drug: Placebo; Drug: Magnesium Sulfate

Study type: Interventional

Funder types: Other

Identifiers

NCT04013243

B-1902/523-007

Details and patient eligibility

About

It is well known that magnesium enhances the effect of neuromuscular blocking agents such as rocuronium. However, it is not known how much magnesium can reduce neuromuscular blocking agents in maintaining deep neuromuscular blockade. Through this study, the investigators will quantitatively analyze the rocuronium saving effect of magnesium.

Full description

It is well known that magnesium potentiate the effect of neuromuscular blocking agents. It prolonged the duration of rocuronium and reduces the onset time of rocuronium. Magnesium acts on motor end plate, where magnesium reduces the release of prejunctional acetylcholine, thereby decreasing the muscle membrane excitability. However, the quantitative rocuronium saving effect of magnesium is not clear. This study's hypothesis is that magnesium would reduce the amount of rocuronium. And the investigators want to evaluate how much magnesium can reduce the amount of rocuronium. Secondary outcome is the effects of magnesium on recovery time, postoperative pain, nausea and vomiting.

Enrollment: 68 patients

Sex: Male

Ages: 20 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Patients who undergo elective robot assisted radical prostatectomy, between 20 and 80 years with a American Society of Anesthesiologists physical status classification of I or II

Exclusion criteria

• Conduction abnormalities in preoperative EKG such as Atrioventricular block, sinus pause
• Glomerular filtration rate <60ml/min/1.73m2
• Allergy to rocuronium, sugammadex, magnesium
• Medications that interfered with muscle activity
• Neuromuscular disease
• Hypermagnesemia

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

68 participants in 2 patient groups, including a placebo group

Magnesium Sulfate group

Active Comparator group

Description:

magnesium sulphate 50mg/kg in normal saline 50ml infusion for 10minutes for loading dose followed by 15mg/kg/hr for continuous infusion

Treatment:

Drug: Magnesium Sulfate

Placebo group

Placebo Comparator group

Description:

Normal Saline 50ml infusion for loading dose followed by continuous infusion for same dose of magnesium.

Treatment:

Drug: Placebo